Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Withdrawn before enrolling · Phase 4

Conditions studied: HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer, Stage IA Breast Cancer

In brief

This pilot clinical trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells. Endocrine therapies such as aromatase inhibitors and selective estrogen receptor modulators may lessen the amount of estrogen made by the body.

Key facts

Study ID

NCT03238703

Run by

Fred Hutchinson Cancer Center

People needed

0

Starts

2018-09-01

Expected to finish

2025-03-14

Last updated by the study team

2018-12-27

Who can join

Age: 60 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Able to provide written informed consent
• A diagnosis of invasive breast cancer, with or without an in situ component, that is:
• Originally identified by screening mammography
• Characterized by standard diagnostic mammography +/- breast ultrasound
• Clinically node negative
• Confirmed by breast magnetic resonance imaging (MRI) in a facility that maintains active American College of Radiology (ACR) accreditation to be of low clinical stage (=< 2 cm, node negative, unifocal invasive)
• Estrogen receptor (ER) and progesterone receptor (PR) Allred scored, each > 5/8
• Her2 negative using American Society of Clinical Oncology (ASCO)-College of American Pathologists (CAP) guidelines
• ki-67 proliferation scored, < 20%
• Clinical Nottingham grade 1 or 2
• Scored on the MammaPrint 70-gene breast cancer recurrence assay as low risk
• Prior to the discovery of the breast cancer, clinically post-menopausal as defined as: i) one or more years from last menses; or ii) history of oophorectomy; or iii) follicle stimulating hormone (FSH) test result in the post-menopause reference range
• Willing to accept oral endocrine therapy with a third generation aromatase inhibitor (AI) or selective estrogen receptor modifier (SERM)
• Willing to undergo routine surveillance with breast ultrasound and/or mammography

You may not qualify if…

• Known contraindication to aromatase inhibitor or SERM therapy
• Pregnant at time of or within prior year of diagnosis
• Clinically detected or palpable disease prior to biopsy in either breast or ipsilateral axilla
• Prior history of invasive breast cancer or ductal breast carcinoma in situ (DCIS)
• Prior use of aromatase inhibitor therapy apart from assisted reproduction
• Prior use of SERM
• Unmanaged/uncontrolled mental health disorder
• Life expectancy < 6 months (m) for any cause
• Biopsy confirmed multifocal, multicentric, or contralateral disease that is invasive or non-invasive
• DCIS with focal invasion

Where it is running

• Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.